← Pharming Group NV overview

Pharming Group NV vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pharming Group NV (PHARM.AS)

Q3 2026
▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

  • Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.

    The guidance cut is the single biggest negative force behind the stock's move this period.

  • Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.

    It is a new negative overhang that can affect the stock beyond the one-day drop.

  • Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.

    These approvals are the main positive counterweight to the weak RUCONEST story.

  • CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.

    An abrupt CEO departure is a fresh governance risk that can hold the stock back.

August 2026
▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

  • Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.

    The guidance cut is the single biggest negative force behind the stock's move this period.

  • Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.

    It is a new negative overhang that can affect the stock beyond the one-day drop.

  • Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.

    These approvals are the main positive counterweight to the weak RUCONEST story.

  • CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.

    An abrupt CEO departure is a fresh governance risk that can hold the stock back.

Latest
▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

  • Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.

    The guidance cut is the single biggest negative force behind the stock's move this period.

  • Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.

    It is a new negative overhang that can affect the stock beyond the one-day drop.

  • Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.

    These approvals are the main positive counterweight to the weak RUCONEST story.

  • CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.

    An abrupt CEO departure is a fresh governance risk that can hold the stock back.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

August 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.